{"entity":{"id":"pacific-2","kind":"trial","name":"PACIFIC-2","aka":[],"tldr":"PACIFIC-2 asked whether starting durvalumab during chemoradiotherapy, rather than after it, would help people with stage III lung cancer; it did not, so the sequence established by the original PACIFIC trial stands.","summary":"PACIFIC established durvalumab given after chemoradiotherapy as the standard for unresectable stage III non-small-cell lung cancer. PACIFIC-2 tested the more aggressive schedule of starting durvalumab at the same time as platinum-based chemoradiotherapy and continuing it afterwards, against placebo, in 328 patients. The primary endpoint was progression-free survival.\n\nThe trial did not show a statistically significant improvement in progression-free survival, and more patients in the durvalumab arm stopped treatment early for adverse events. Consolidation after chemoradiotherapy therefore remains the way durvalumab is used in this setting.","status":"negative","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov NCT03519971","url":"https://clinicaltrials.gov/study/NCT03519971"}],"tags":["subtype-trials"],"related":[],"cancers":["stage-iii-unresectable-nsclc","nsclc","lung-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["durvalumab","cisplatin","carboplatin"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["jeffrey-bradley"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03519971","phase":"3","setting":"Unresectable stage III non-small-cell lung cancer: durvalumab or placebo given together with platinum chemoradiotherapy and continued afterwards","sponsor":"AstraZeneca","result":"Concurrent durvalumab with chemoradiotherapy did not significantly improve progression-free survival over chemoradiotherapy alone.","yearReported":2024,"enrolled":328,"outcomes":[]},"route":"/trials/pacific-2/","neighbours":{"cancer":[{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"stage-iii-unresectable-nsclc","kind":"cancer","name":"Unresectable stage III non-small-cell lung cancer","route":"/cancers/stage-iii-unresectable-nsclc/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"person":[{"id":"jeffrey-bradley","kind":"person","name":"Jeffrey D. Bradley","route":"/people/jeffrey-bradley/"}]}}